YCT-529, developed by US scientists, moves to early-stage phase 2 trial in New Zealand. Study published in Nature Communications showed it to be 99% effective in preclinical studies.
Nick Jonas is not trying to modernise the mangalsutra, but his gesture shows that choices can be equal. If commitment must be flaunted, it need not be gendered.
COMMENTS